CA3210092A1 - Combination of reboxetine and a muscarinic receptor antagonist (mra) for use in treating sleep apnea - Google Patents

Combination of reboxetine and a muscarinic receptor antagonist (mra) for use in treating sleep apnea Download PDF

Info

Publication number
CA3210092A1
CA3210092A1 CA3210092A CA3210092A CA3210092A1 CA 3210092 A1 CA3210092 A1 CA 3210092A1 CA 3210092 A CA3210092 A CA 3210092A CA 3210092 A CA3210092 A CA 3210092A CA 3210092 A1 CA3210092 A1 CA 3210092A1
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
acceptable salt
reboxetine
oxybutynin
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3210092A
Other languages
English (en)
French (fr)
Inventor
Lawrence G. Miller
Ronald FARKAS
Luigi TARANTO-MONTEMURRO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apnimed Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3210092A1 publication Critical patent/CA3210092A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3210092A 2021-03-04 2022-03-03 Combination of reboxetine and a muscarinic receptor antagonist (mra) for use in treating sleep apnea Pending CA3210092A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163156463P 2021-03-04 2021-03-04
US63/156,463 2021-03-04
PCT/US2022/018604 WO2022187420A1 (en) 2021-03-04 2022-03-03 Combination of reboxetine and a muscarinic receptor antagonist (mra) for use in treating sleep apnea

Publications (1)

Publication Number Publication Date
CA3210092A1 true CA3210092A1 (en) 2022-09-09

Family

ID=80999274

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3210092A Pending CA3210092A1 (en) 2021-03-04 2022-03-03 Combination of reboxetine and a muscarinic receptor antagonist (mra) for use in treating sleep apnea

Country Status (8)

Country Link
US (1) US20240139200A1 (https=)
EP (1) EP4301353A1 (https=)
JP (1) JP2024508498A (https=)
KR (1) KR20230154186A (https=)
CN (1) CN116916909A (https=)
AU (1) AU2022231133A1 (https=)
CA (1) CA3210092A1 (https=)
WO (1) WO2022187420A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CA2431041A1 (en) * 2001-01-02 2002-07-11 Pharmacia & Upjohn Company New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
US20070196481A1 (en) * 2002-07-25 2007-08-23 Amidon Gregory E Sustained-release tablet composition
GEAP202416602A (en) * 2017-04-28 2024-10-10 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea
KR102874891B1 (ko) * 2018-01-30 2025-10-21 애프니메드, 인코포레이티드 (델라웨어) 수면 무호흡증을 치료하기 위한 방법 및 조성물

Also Published As

Publication number Publication date
CN116916909A (zh) 2023-10-20
EP4301353A1 (en) 2024-01-10
AU2022231133A1 (en) 2023-09-21
US20240139200A1 (en) 2024-05-02
JP2024508498A (ja) 2024-02-27
KR20230154186A (ko) 2023-11-07
WO2022187420A1 (en) 2022-09-09

Similar Documents

Publication Publication Date Title
US20260007618A1 (en) Methods and compositions for treating sleep apnea
JP2021516218A (ja) 睡眠時無呼吸を治療するための方法および組成物
JP2025084754A (ja) 睡眠時無呼吸を治療するための方法および組成物
US20240075035A1 (en) Methods and compositions for treating sleep apnea
US20240277719A1 (en) Norepinephrine reuptake inhibitors for treating sleep apnea
US20230135373A1 (en) Methods and compositions for treating sleep apnea
US20240139200A1 (en) Combination of reboxetine and a muscarinic receptor antagonist (mra) for use in treating sleep apnea
US20240173337A1 (en) Methods and compositions for treating sleep apnea
KR20240053061A (ko) 수면 무호흡증을 치료하기 위한 방법 및 조성물
US20250302814A1 (en) Methods and compositions for treating sleep apnea
US20250009720A1 (en) Methods and compositions for treating sleep apnea
AU2023335927A1 (en) Methods and compositions for treating sleep apnea
WO2024220343A1 (en) Combination of a norepinephrine reuptake inhibitor and a melatonin receptor agonist for use in treating sleep apnea
CN117615764A (zh) 用于治疗睡眠呼吸暂停的去甲肾上腺素再摄取抑制剂

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241220

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241220

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241220

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251211

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251211